<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00652184</url>
  </required_header>
  <id_info>
    <org_study_id>ARYS-0701</org_study_id>
    <nct_id>NCT00652184</nct_id>
  </id_info>
  <brief_title>Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)</brief_title>
  <official_title>Phase 2/3 Multi-Center, Double-Blind, Controlled Trial Comparing Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir, and Combination Topical ARYS-01 Cream /Oral Valaciclovir for Treatment of Herpes Zoster in Immunocompetent Patients 18 Years of Age or Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>aRigen Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>aRigen Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, randomized, 4-arm, placebo-controlled, double-blind efficacy study of ARYS-01
      (sorivudine) cream 3%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      More than 95% of people are infected with varicella Zoster virus (VZV) at one time of life or
      another. Primary VZV infection manifests as varicella (chicken pox). The virus then
      establishes a latent infection of the sensory ganglia from which it may reactivate years
      later to produce the clinical syndrome of Herpes Zoster (shingles). The initial cutaneous VZV
      lesions are pruritic, erythematous macules; and the lesions progress through maculopapular
      stage to vesicular, ulceration and crusting phases. The crusting phase signals the beginning
      of the healing process, and begins with clouding of the vesicular fluid, within about 24 to
      48 h after the appearance of each lesion. This is a Phase 2 study to assess: 1) the overall
      benefit of ARYS-01 (sorivudine) cream 3% vs. Placebo cream (with immediate or delayed use of
      Valaciclovir therapy) on Herpes Zoster rash healing rates and postherpetic neuralgia (PHN),
      2) the efficacy of ARYS-01 cream 3% vs. Placebo cream, prior to initiation of Valaciclovir,
      to build evidence for monotherapy treatment benefit of ARYS-01 cream on the initial onset of
      Herpes Zoster symptoms, 3) the efficacy of ARYS-01 cream 3% vs. Placebo cream, with immediate
      or delayed initiation of Valaciclovir, for synergetic effects on the initial onset of Herpes
      Zoster symptoms.

      The primary efficacy endpoint is the effect of ARYS-01 cream (with or without Valaciclovir)
      on the reduction of the crusting stage of VZV rash present at Day 8. Secondary endpoints
      include time to cessation of new lesion formation, and time to cessation of Zoster-associated
      pains, pain intensity, rash healing and size reduction, and lesion dissemination.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">September 2009</completion_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect of ARYS-01 (sorivudine) cream (with or without Valaciclovir) on the reduction of the crusting stage of VZV rash present at Day 8.</measure>
    <time_frame>Day 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time to cessation of new lesion formation, and time to cessation of Zoster-associated pains, pain intensity, rash healing and size reduction, and lesion dissemination.</measure>
    <time_frame>Day 4</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Herpes Zoster</condition>
  <condition>Postherpetic Neuralgia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cream BID for 10 days and placebo valaciclovir caplets TID from days 1-3 and active valaciclovir caplets 1 gram TID from days 4-10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo cream BID for 10 days and active valaciclovir caplets TID from days 1-10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active cream BID for 10 days and placebo valaciclovir caplets TID from days 1-3 and active valaciclovir caplets 1 gram TID from days 4-10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Active cream BID for 10 days and active valaciclovir caplets TID from days 1-10</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARYS-01 (sorivudine) cream 3% or placebo cream</intervention_name>
    <description>sorivudine cream 3% or placebo cream twice daily for 10 days</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>ARYS-01 cream 3%</other_name>
    <other_name>sorivudine cream 3%</other_name>
    <other_name>topical sorivudine 3%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo cream and placebo valaciclovir</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valaciclovir</intervention_name>
    <description>active valaciclovir</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least 18 years of age

          -  diagnosed with herpes zoster

          -  confirmed for VZV with lesion swab at screening and subsequent PCR test.

          -  contraception for women of child-bearing potential

          -  be able to communicate with investigator and compliant

        Exclusion Criteria:

          -  cytotoxic or immunosuppressive drugs within 3 mos, 5-FU or its pro-drugs, tricyclic
             antidepressants, probenecid, topical or systemic antiviral drugs or immunomodulatory
             agents for viral infection

          -  herpes zoster ophthalmicus

          -  female patients who are pregnant and/or nursing or planning a pregnancy

          -  congenital, acquired or corticosteroid-induced immunodeficiency, including malignancy

          -  renal insufficiency or creatinine level &gt;2mg/dL

          -  clinical significant liver enzyme abnormalities and any other laboratory abnormalities
             determined by the screening lab

          -  history of intolerance or hypersensitivity to the cream components

          -  current significant skin disease within affected dermatome

          -  history of positive result for hepatitis B surface antigen, hepatitis C virus, or HIV

          -  current participation in another clinical drug research study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ARYS-0701 Site 3</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARYS-0701 Site 6</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARYS-0701 Site 7</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARYS-0701 Site 8</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARYS-0701 Site 9</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARYS-0701 Site 10</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARYS-0701 Site 11</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARYS-0701 Site 4</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARYS-0701 Site 12</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARYS-0701 Site 1</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2008</study_first_posted>
  <last_update_submitted>October 3, 2008</last_update_submitted>
  <last_update_submitted_qc>October 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2008</last_update_posted>
  <responsible_party>
    <name_title>President and Chief Executive Officer</name_title>
    <organization>aRigen Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>antiviral</keyword>
  <keyword>herpes zoster</keyword>
  <keyword>postherpetic neuralgia</keyword>
  <keyword>varicella zoster virus</keyword>
  <keyword>shingles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
    <mesh_term>Sorivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

